SATELIA

About SATELIA

Satelia, established in 2017, is a French HealthTech firm developing a remote medical monitoring platform for patients with chronic illnesses. The company was founded by Nicolas Pages, who was an anesthesiology and intensive care intern at the Bordeaux University Hospital at the time, and Paul Tiba, then director of a medical repatriation airline. Their combined experiences highlighted a gap in the healthcare system for continuous, remote patient management, which catalyzed the creation of Satelia.

The company operates in the digital health market, providing its services to hospitals, clinics, and independent physicians, with a notable presence in over 500 healthcare facilities in France. Satelia's business model is centered on a B2B approach, and its revenue is substantially supported by the French Social Security system, which reimburses the service at 100% for eligible patients, making it free for both patients and healthcare providers. The company has secured approximately $9.91 million in funding, including a significant Series A round in October 2022 led by Impact Partners.

Satelia's core product is the Satelia® Cardio, a CE-marked medical device classified as a Software-as-a-Medical Device (SaMD). This platform facilitates the telemonitoring of chronic conditions, with a primary focus on heart failure. It functions without requiring patients to install an application or use connected devices; instead, patients respond to simple, regular questionnaires via a web link sent by SMS. The system's algorithm analyzes patient-reported symptoms and weight to generate a risk score, categorizing the patient's status as green, orange, or red to alert medical teams of potential health deterioration. To address the digital divide, Satelia employs a dedicated paramedical team, named Télesphore, who contacts patients by phone to collect data, ensuring the solution is accessible to all, regardless of their digital literacy. This dual digital and human-centric approach is a key feature of their service.

The efficacy of the Satelia® Cardio solution is supported by the TELESAT-HF study, a large-scale observational study involving nearly 20,000 patients in France. The results indicated that the remote monitoring program was associated with a 36% reduction in all-cause mortality and a 17% decrease in emergency hospital visits among heart failure patients compared to standard care. Following these results, Satelia Cardio became the first remote monitoring solution for heart failure to obtain a brand-name reimbursement from the French health insurance system.